-
Innovation Ranking
NewInnovation Ranking – Morphic Holding Inc
Morphic Holding Inc (Morphic Therapeutic) is biopharmaceutical company that develops oral integrin therapies for the treatment of autoimmune, cardiovascular and metabolic diseases and fibrosis and cancer based on its Morphic integrin technology platform (MInT Platform). Its lead products candidate MORF - O57 (α4β7) is intended for the treatment of inflammatory bowel disease (IBD). It also developing Next Gen α4β7 Inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis. The company operates in Delaware and Massachusetts, the US. Morphic...
-
Product Insights
NewNet Present Value Model: Morphic Holding Inc’s MORF-057
Empower your strategies with our Net Present Value Model: Morphic Holding Inc's MORF-057 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Morphic Holding Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Morphic Holding Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BOLD-100 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BOLD-100 in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BOLD-100 in Gastric Cancer Drug Details: BOLD-100 (IT-139, NKP-1339) is under development...
-
Product Insights
Pouchitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Pouchitis - Drugs In Development, 2023’, provides an overview of the Pouchitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pouchitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Eosinophilic Esophagitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Eosinophilic Esophagitis - Drugs In Development, 2023’, provides an overview of the Eosinophilic Esophagitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Eosinophilic Esophagitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Myelofibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Myelofibrosis - Drugs In Development, 2023’, provides an overview of the Myelofibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myelofibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Esophageal Diseases – Drugs In Development, 2023
Global Markets Direct’s, ‘Esophageal Diseases - Drugs In Development, 2023’, provides an overview of the Esophageal Diseases pipeline landscape. The report provides comprehensive information on the therapeutics under development for Esophageal Diseases, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Esophagitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Esophagitis - Drugs In Development, 2023’, provides an overview of the Esophagitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Esophagitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Pulmonary Arterial Hypertension – Drugs In Development, 2023
Global Markets Direct’s, ‘Pulmonary Arterial Hypertension - Drugs In Development, 2023’, provides an overview of the Pulmonary Arterial Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...